Skip to content

Protective effect with combined Dexmedetomidine and Ulinastatin preconditioning on liver ischemia-reperfusion injury in laparoscopic liver resection

Protective effect with combined Dexmedetomidine and Ulinastatin preconditioning on liver ischemia-reperfusion injury in laparoscopic liver resection

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300067404
Enrollment
Unknown
Registered
2023-01-06
Start date
2023-01-09
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

laparoscopic liver resection

Interventions

Group B:Ulinastatin
Group C:Dexmedetomidine and Ulinastatin
Group D:0.9% Saline(placebo)

Sponsors

The First Affiliated Hospital,The Air Force Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1)Patients proposed to undergo laparoscopic liver resection (intraoperative hepatic blood flow block is required); 2)ASA grade I-III; 3)Child-Pugh score: Grade Child A or Grade Child B; 4)Voluntarily signing of the informed consent form.

Exclusion criteria

Exclusion criteria: 1)Age is <18 years old; 2)Child-Pugh score: Grade Child C; 3)Severe organ dysfunction such as the heart, lung, kidney, brain and other major organs; 4)Patients with liver trauma, living donor of liver transplantation, and a history of liver surgery or radiofrequency ablation; 5)Patients with II block or above or 2 or more bundle branch block; 6)Patients with pregnancy, drug addiction, and mental illness; 7)Patients allergied to any study drug; 8)Patients participating in other clinical trial studies.

Design outcomes

Primary

MeasureTime frame
ALT;

Secondary

MeasureTime frame
AST;TBIL;DBILI;IBILI;ALP;GGP;ALB;Lac;Time of hospital stay;complications(CDC-CCI);IL-6;CRP;

Countries

China

Contacts

Public Contactzhu zhenghua

The First Affiliated Hospital,The Air Force Medical University

2829204077@qq.com13720770848

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026